

Our Ref: 109
February 2024

Re: Your request made under the Freedom of Information Act 2000

I am researching the usage of high-cost drugs in ophthalmology. Your answers to the following questions will be highly appreciated.

1. For the 4 months from September to December 2023, how many patients received the following intra-vitreous treatments for any eye condition:

Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Faricimab
Ranibizumab - Lucentis
Ranibizumab - Ongavia

2. For the patients above, how many were new to intra-vitreous treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.

Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Faricimab
Ranibizumab - Lucentis
Ranibizumab - Ongavia

- **Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.**